AmCham EU

Launch of The Transatlantic Economy 2025

17 Mar 2025

All committees

As headlines blare that Europe and the US are drifting apart, commercial ties between the two sides – the deepest and broadest between any two regions in history – are accelerating. In a new study, authors Daniel Hamilton, Senior Fellow at the Foreign Policy Institute of Johns Hopkins University’s Paul H. Nitze School of Advanced International Studies, and Joseph Quinlan, Senior Fellow at the Transatlantic Leadership Network, value the transatlantic economy at a new estimated high of $9.5 (€8.7) trillion in 2024, up from $8.7 (€8) trillion the previous year. This figure comprises an estimated record $2 (€1.8) trillion in goods and services trade between Europe and the US and $7.5 (€6.9) trillion in combined affiliate sales.

US steel and aluminium tariffs: American business in Europe responds

12 Mar 2025

All committees

Today, the US administration imposed tariffs on steel and aluminium, including EU imports. In response, Malte Lohan, CEO, American Chamber of Commerce to the EU (AmCham EU), expressed the opposition of American business in Europe to the decision, stating: ‘The US administration’s new steel and aluminium tariffs are not the same as those imposed in 2018. They are more stringent and cover a range of downstream products, meaning their impact will be harsher and affect even more sectors.’

Fostering a competitive environment through the Critical Medicines Act

11 Mar 2025

Healthcare

Securing robust and diversified life sciences supply chains is essential for Europe to maintain a continuous and stable provision of medical products, both domestically and globally, especially during crises. Today, the European Commission presented the Critical Medicines Act, which represents a vital opportunity to achieve this goal by: ensuring the continued functioning of open global supply chains to deliver timely patient access; promoting collaboration with international partners and all stakeholders to improve global supply chain flexibility, diversification and resilience; strengthening open trade in life sciences and avoiding restrictive or protectionist measures, which could negatively impact production, supply resilience and availability.